首页|期刊导航|癌症生物学与医学（英文版）|Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer

Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer

Yaxin Zhao Han Wang Ying Wang Yizhou Jiang Xin Hu Zhiming Shao

癌症生物学与医学（英文版）2026，Vol.23Issue(3)：374-391,18.

癌症生物学与医学（英文版）2026，Vol.23Issue(3)：374-391,18.DOI:10.20892/j.issn.2095-3941.2025.0691

Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer

Yaxin Zhao ¹Han Wang ²Ying Wang ²Yizhou Jiang ¹Xin Hu ³Zhiming Shao¹

作者信息

1. Key Laboratory of Breast Cancer in Shanghai,Department of Breast Surgery,Fudan University Shanghai Cancer Center,Shanghai 200032,China||Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China
2. Key Laboratory of Breast Cancer in Shanghai,Department of Breast Surgery,Fudan University Shanghai Cancer Center,Shanghai 200032,China
3. Key Laboratory of Breast Cancer in Shanghai,Department of Breast Surgery,Fudan University Shanghai Cancer Center,Shanghai 200032,China||Precision Cancer Medical Center Affiliated to Fudan University Shanghai Cancer Center,Shanghai 201315,China
折叠

摘要

关键词

Triple-negative breast cancer/luminal androgen receptor subtype/ERBB2 mutation/cellular senescence/immunotherapy resistance

Key words

Triple-negative breast cancer/luminal androgen receptor subtype/ERBB2 mutation/cellular senescence/immunotherapy resistance

引用本文复制引用

Yaxin Zhao,Han Wang,Ying Wang,Yizhou Jiang,Xin Hu,Zhiming Shao..Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer[J].癌症生物学与医学（英文版）,2026,23(3):374-391,18.

基金项目

This work received funding from the Ministry of Science and Technology of China(Grant Nos.2023YFF1205003,2023YFF0613304,and 2023YFC3402504),the National Key R&D Program of China(Grant No.2023YFF0613300,2023YFF1205003),and the National Natural Science Foundation of China(Grant Nos.82473499,82272957,and 82303735). （Grant Nos.2023YFF1205003,2023YFF0613304,and 2023YFC3402504）

癌症生物学与医学（英文版）

ISSN：2095-3941

访问量0

下载量0

段落导航